



A Pfizer Company

SAFETY DATA SHEET

Revision date: 26-Jul-2017

Version: 1.1

Page 1 of 10

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Lidocaine Hydrochloride Injection (Hospira, Inc.)

Trade Name: Lignocaine Injection

Synonyms: Lidocaine

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product anesthetic agent

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

SAFETY DATA SHEET

Material Name: Lidocaine Hydrochloride Injection (Hospira, Inc.)

Page 2 of 10

Revision date: 26-Jul-2017

Version: 1.1

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Lidocaine Hydrochloride	73-78-9	200-803-8	Acute Tox.4 (H302)	1-2
Sodium chloride	7647-14-5	231-598-3	Not Listed	*
SODIUM HYDROXIDE	1310-73-2	215-185-5	Skin Corr. 1A (H314)	**
HYDROCHLORIC ACID	7647-01-0	231-595-7	Skin Corr.1B (H314) STOT SE 3 (H335)	**

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for injection	7732-18-5	231-791-2	Not Listed	*

Additional Information:

* Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

SAFETY DATA SHEET

Material Name: Lidocaine Hydrochloride Injection (Hospira, Inc.)

Page 3 of 10

Revision date: 26-Jul-2017

Version: 1.1

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Contain the source of the spill or leak if it is safe to do so. Collect spill with a non-combustible absorbent material and transfer to labeled container for disposal.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Sodium chloride

Latvia OEL - TWA 5 mg/m³

Lithuania OEL - TWA 5 mg/m³

SODIUM HYDROXIDE

ACGIH Ceiling Threshold Limit: 2 mg/m³

Australia PEAK 2 mg/m³

Austria OEL - MAKs 2 mg/m³

Bulgaria OEL - TWA 2.0 mg/m³

Czech Republic OEL - TWA 1 mg/m³

Estonia OEL - TWA 1 mg/m³

France OEL - TWA 2 mg/m³

Greece OEL - TWA 2 mg/m³

Hungary OEL - TWA 2 mg/m³

Japan - OELs - Ceilings 2 mg/m³

Latvia OEL - TWA 0.5 mg/m³

OSHA - Final PELs - TWAs: 2 mg/m³

SAFETY DATA SHEET

Material Name: Lidocaine Hydrochloride Injection (Hospira, Inc.)

Page 4 of 10

Revision date: 26-Jul-2017

Version: 1.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Poland OEL - TWA	0.5 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	1 mg/m ³
Switzerland OEL - TWAs	2 mg/m ³

HYDROCHLORIC ACID

ACGIH Ceiling Threshold Limit:	2 ppm
Australia PEAK	5 ppm
	7.5 mg/m ³
Austria OEL - MAKs	5 ppm
	8 mg/m ³
Belgium OEL - TWA	5 ppm
	8 mg/m ³
Bulgaria OEL - TWA	5 ppm
	8.0 mg/m ³
Cyprus OEL - TWA	5 ppm
	8 mg/m ³
Czech Republic OEL - TWA	8 mg/m ³
Estonia OEL - TWA	5 ppm
	8 mg/m ³
Germany - TRGS 900 - TWAs	2 ppm
	3 mg/m ³
Germany (DFG) - MAK	2 ppm
	3.0 mg/m ³
Greece OEL - TWA	5 ppm
	7 mg/m ³
Hungary OEL - TWA	8 mg/m ³
Ireland OEL - TWAs	5 ppm
	8 mg/m ³
Italy OEL - TWA	5 ppm
	8 mg/m ³
Japan - OELs - Ceilings	2 ppm
	3.0 mg/m ³
Latvia OEL - TWA	5 ppm
	8 mg/m ³
Lithuania OEL - TWA	5 ppm
	8 mg/m ³
Luxembourg OEL - TWA	5 ppm
	8 mg/m ³
Malta OEL - TWA	5 ppm
	8 mg/m ³
Netherlands OEL - TWA	8 mg/m ³
Poland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	5 ppm
	8 mg/m ³
Romania OEL - TWA	5 ppm
	8 mg/m ³
Slovakia OEL - TWA	5 ppm
	8.0 mg/m ³
Slovenia OEL - TWA	5 ppm
	8 mg/m ³

SAFETY DATA SHEET

Material Name: Lidocaine Hydrochloride Injection (Hospira, Inc.)

Page 5 of 10

Revision date: 26-Jul-2017

Version: 1.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Spain OEL - TWA	5 ppm 7.6 mg/m ³
Switzerland OEL - TWAs	2 ppm 3.0 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³

Lidocaine Hydrochloride

Pfizer Occupational Exposure Band (OEB): OEB 2 (control exposure to the range of 100ug/m³ to < 1000ug/m³)

Sodium chloride

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands: Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Solution	Color:	Clear, colorless
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	5-7
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Lidocaine Hydrochloride

No data available

SAFETY DATA SHEET

Material Name: Lidocaine Hydrochloride Injection (Hospira, Inc.)

Page 6 of 10

Revision date: 26-Jul-2017

Version: 1.1

9. PHYSICAL AND CHEMICAL PROPERTIES

Water for injection

No data available

Sodium chloride

No data available

HYDROCHLORIC ACID

No data available

SODIUM HYDROXIDE

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: There are no data for this formulation. The information included in this section describes the potential hazards of the individual ingredients.

Short Term: Harmful if swallowed. May cause mild eye irritation. May cause slight skin irritation. (based on components) Drugs of this class have been associated with rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure.

Known Clinical Effects: Adverse effects associated with therapeutic use include dizziness, nervousness, agitation, drowsiness, apprehension, euphoria, blurred/double vision, slurred speech, tremors, convulsions, and seizure. Respiratory depression and arrest may follow. Other, more serious effects seen with IV use of this drug, particularly when it is administered rapidly, are cardiovascular collapse, central nervous system depression, and/or hypotension.

Acute Toxicity: (Species, Route, End Point, Dose)

Lidocaine Hydrochloride

SAFETY DATA SHEET

Material Name: Lidocaine Hydrochloride Injection (Hospira, Inc.)

Page 7 of 10

Revision date: 26-Jul-2017

Version: 1.1

11. TOXICOLOGICAL INFORMATION

Rat Oral LD50 317 mg/kg
Rat Para-periosteal LD50 25mg/kg
Rat Intraperitoneal LD50 133mg/kg
Mouse Oral LD50 292mg/kg
Mouse Intravenous LD50 19.5mg/kg

Sodium chloride

Rat Oral LD50 3000 mg/kg
Mouse Oral LD50 4000 mg/kg

HYDROCHLORIC ACID

Rat Oral LD 50 238-277 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Lidocaine Hydrochloride

Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Sodium chloride

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Lidocaine Hydrochloride

Embryo / Fetal Development Rat Subcutaneous 30 mg/kg NOAEL Not teratogenic
Embryo / Fetal Development Rat Intraperitoneal 56 mg/kg NOAEL Not Teratogenic
Embryo / Fetal Development Rat Intraperitoneal 72 mg/kg/day NOAEL Not Teratogenic
Embryo / Fetal Development Rat Intravenous 500 mg/kg/day LOAEL Fetotoxicity
Embryo / Fetal Development Rat Intraperitoneal 6 mg/kg LOAEL Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Lidocaine Hydrochloride

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative
In Vitro Chromosome Aberration Human Lymphocytes Negative
In Vivo Micronucleus Mouse Negative

HYDROCHLORIC ACID

Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vivo Micronucleus Rat Negative

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

HYDROCHLORIC ACID

IARC:

Group 3 (Not Classifiable)

SAFETY DATA SHEET

Material Name: Lidocaine Hydrochloride Injection (Hospira, Inc.)

Page 8 of 10

Revision date: 26-Jul-2017

Version: 1.1

12. ECOLOGICAL INFORMATION

Environmental Overview:	Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:	Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.
---------------------------------	---

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Lidocaine Hydrochloride	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-803-8

Sodium chloride

SAFETY DATA SHEET

Material Name: Lidocaine Hydrochloride Injection (Hospira, Inc.)

Page 9 of 10

Revision date: 26-Jul-2017

Version: 1.1

15. REGULATORY INFORMATION

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-598-3

Water for injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

SODIUM HYDROXIDE

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb 454 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5 Schedule 6
EU EINECS/ELINCS List	215-185-5

HYDROCHLORIC ACID

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb 2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	500 lb
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	5000 lb
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5 Schedule 6
EU EINECS/ELINCS List	231-595-7

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
 Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage
 Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

SAFETY DATA SHEET

Material Name: Lidocaine Hydrochloride Injection (Hospira, Inc.)

Page 10 of 10

Revision date: 26-Jul-2017

Version: 1.1

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Updated Section 16 - Other Information.

Revision date: 26-Jul-2017

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet